- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05375799
Clinical and Electronic Record for Patients With COVID-19 Treated With the Assisted Breathing Helmet - ELMO in Ceará (COVID-19)
Continuous positive airway pressure (CPAP) with a helmet-like interface has been described as a safe strategy, with minimal contamination of the environment, improving the oxygenation of patients with acute respiratory failure (ARF) by COVID-19, avoiding intubation in more than half of the cases. ELMOcpap, developed in Ceará, was a great ally in the treatment of these cases during the pandemic in the state. It is estimated that among public and private services, more than 1.400 ELMOs have been applied to patients with COVID-19. However, the determining factors of the success and failure of its use in the different institutions in which it has been applied are still unknown. Therefore, it is necessary to survey all data associated with the use of the device.
Objectives: 1. To describe the effects of ELMO in the treatment of patients with hypoxemic respiratory failure due to COVID-19 in a database, in a systematic and standardized way, on clinical history, efficacy, safety, modes, duration of use, the occurrence of adverse events and early predictors of failure. 2. Determine the intubation rate of patients with COVID-19 hypoxemic respiratory failure who used the ELMO. 3. Identify the mortality rate of patients with hypoxemic respiratory failure due to COVID-19 who used the ELMO.
Methods: This is a retrospective, multicenter, observational, cohort study of recorded data from patients with COVID-19 hypoxemic respiratory failure who were treated with the ELMO. An online electronic form will be developed with REDCap, where the responsible investigator of each institution will be responsible for filling in the participants' data, ensuring adherence to the protocol and analysis will be carried out of the data of the patients of the participating services of the research that used the ELMO as treatment.
Panoramica dello studio
Descrizione dettagliata
An online electronic form will be developed with REDCap, where the responsible investigator of each institution will be responsible for filling in the participants' data, ensuring adherence to the protocol.
The researchers involved will undergo qualified training and will receive a video, showing step-by-step how REDCap works, so that there are no doubts about the data collection process and to ensure the standardization of the collection protocol.
An explanation of the nature and objectives of the study will be presented to the research subjects, as well as its importance to society, health professionals and researchers.
The investigators will visit the hospital at least five times a week in the morning, afternoon and/or night shifts, for data collection, with monitoring and collection of outcomes being performed daily.
Tipo di studio
Iscrizione (Anticipato)
Contatti e Sedi
Contatto studio
- Nome: Luiza G Frota, PHD
- Numero di telefono: 8499 558533668499
- Email: gabigomes1@hotmail.com
Luoghi di studio
-
-
Ceara
-
Fortaleza, Ceara, Brasile, 60135-285
- Reclutamento
- Hospital Leonardo Da Vinci
-
Contatto:
- Marcelo A Holanda, PHD
- Numero di telefono: +558531011398
- Email: cep@esp.ce.gov.br
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Patients with COVID-19, confirmed by laboratory detection of SARS-CoV-2 RNA, who used the Assisted Breathing Helmet - ELMO in referral hospitals in Fortaleza, Brazil.
Data will be collected retrospectively from adult patients admitted to the ICU and wards during the COVID-19 pandemic in Fortaleza.
An online electronic form will be developed with REDCap, where the responsible investigator of each institution will be responsible for filling in the participants' data, ensuring adherence to the protocol.
Descrizione
Inclusion Criteria:
- Data from adult patients diagnosed with COVID-19 described in medical records by laboratory detection of RNA of SARS-CoV-2, who used the Assisted Breathing Helmet - ELMO, will be recruited.
Exclusion Criteria:
- Illegible medical records or forms or with incomplete data that make it impossible to collect data will be excluded.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
---|---|
COVID-19 in use of ELMO
This is an observational study, so there are no interventions.
Data will be recruited from adult patients diagnosed with COVID-19, described in medical records, by laboratory detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA, who used the Assisted Breathing Helmet - ELMO.
|
This is an observational study, so there are no interventions. Data will be recruited from adult patients diagnosed with COVID-19, described in medical records, by laboratory detection of SARS-CoV-2 RNA, who used the Assisted Breathing Helmet - ELMO. All the following predictor variables will be collected: demographic and anthropometric data; clinical characteristics of patients (comorbidities, date of onset of symptoms and initial symptoms, hospital admission, laboratory tests, chest X-ray tests, need for intubation or ICU admission); start date of ELMO use, blood gas analysis before and after the first application of ELMO and data related to its use (number of applications, number of days of therapy, total time of therapy, as well as reasons for the interruption and adverse effects ). |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Risk factors for intubation
Lasso di tempo: up to 60 days
|
To evaluate the risk factors for intubation of patients with hypoxemic ARF due to COVID-19 who used the Assisted Breathing Helmet - ELMO.
|
up to 60 days
|
Risk factors for death
Lasso di tempo: up to 90 days
|
To evaluate the risk factors for death of patients with hypoxemic ARF due to COVID-19 who used the Assisted Breathing Helmet - ELMO.
|
up to 90 days
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Time to start ELMO therapy
Lasso di tempo: up to 28 days
|
Time to start using the Assisted Breathing Helmet - ELMO
|
up to 28 days
|
Total time of use ELMO therapy
Lasso di tempo: up to 60 days
|
Total time of use of the Assisted Breathing Helmet - ELMO
|
up to 60 days
|
Adverse events of ELMO
Lasso di tempo: up to 60 days
|
Adverse events with the use of the Assisted Breathing Helmet - ELMO
|
up to 60 days
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Marcelo A Holanda, PHD, Escola Saude Publica
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 4.833.400
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios...CompletatoSequele post acute di COVID-19 | Condizione post COVID-19 | Lungo-COVID | Sindrome cronica da COVID-19Italia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNon ancora reclutamentoSindrome post-COVID-19 | Lungo COVID | Lungo Covid19 | Condizione post COVID-19 | Sindrome post-COVID | Condizione post COVID-19, non specificata | Condizione post-COVIDOlanda
-
Indonesia UniversityReclutamentoSindrome post-COVID-19 | Lungo COVID | Condizione post COVID-19 | Sindrome post-COVID | Lungo COVID-19Indonesia
-
Yang I. PachankisAttivo, non reclutanteInfezione respiratoria da COVID-19 | Sindrome da stress COVID-19 | Reazione avversa al vaccino COVID-19 | Tromboembolia associata a COVID-19 | Sindrome da terapia post-intensiva COVID-19 | Ictus associato a COVID-19Cina
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital; Yulin... e altri collaboratoriReclutamentoCOVID-19 | Sindrome post-COVID-19 | Post-acuto COVID-19 | COVID-19 acutoCina
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaReclutamentoPolmonite COVID-19 | Infezione respiratoria da COVID-19 | Pandemia di covid-19 | Sindrome da distress respiratorio acuto COVID-19 | Polmonite associata a COVID-19 | Coagulopatia associata a COVID 19 | COVID-19 (Coronavirus 2019) | Tromboembolia associata a COVID-19Grecia
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaReclutamentoPandemia di covid-19 | Vaccini contro il covid-19 | Malattia da virus COVID-19Indonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletatoSindrome post-COVID-19 | Sindrome da lungo tempo COVID-19Germania
-
Massachusetts General HospitalReclutamentoSindrome post-acuta da COVID-19 | Lungo COVID | Sequele post acute di COVID-19 | Lungo COVID-19Stati Uniti
Prove cliniche su Clinical Observation
-
University of Wisconsin, MadisonAgency for Healthcare Research and Quality (AHRQ)Reclutamento
-
Fondazione Don Carlo Gnocchi OnlusIstituto di Neuroscienze Consiglio Nazionale delle RicercheReclutamento
-
Centre for Addiction and Mental HealthUniversity Health Network, TorontoCompletatoDisturbo depressivo maggioreCanada
-
University Hospital, RouenCompletato
-
Swiss Group for Clinical Cancer ResearchImmunophotonics, Inc.ReclutamentoTumori solidi avanzatiSvizzera
-
IRCCS Eugenio MedeaMassachusetts Institute of Technology; Politecnico di MilanoReclutamentoDisturbo dello spettro autisticoItalia
-
University of NottinghamEnhanced Recovery After Surgery Group (part of ESPEN)Completato
-
University of LiegeSconosciutoEmorragia | Emergenze | Trauma | CoagulopatiaBelgio
-
Wuerzburg University HospitalCharite University, Berlin, Germany; Goethe University; RWTH Aachen University; Technical... e altri collaboratoriReclutamentoChirurgia | Pazienti di classe ASA III/IV | Sistemi di supporto alle decisioni clinicheGermania
-
St. Louis UniversityTriumph PharmaceuticalsCompletatoParodontite | GengiviteStati Uniti